• OPEN AN ACCOUNT
Indian Indices
Sensex
76,944.28 -12.99
( -0.02%)
Global Indices
Nasdaq
53,227.35 -353.64
(-0.66%)
Dow Jones
7,711.10 -21.66
(-0.28%)
Hang Seng
66,431.13 119.20
(0.18%)
Nikkei 225
10,792.77 -31.49
(-0.29%)
Forex
USD-INR
95.47 -0.01
(-0.01%)
EUR-INR
110.57 -0.67
(-0.60%)
GBP-INR
129.19 -0.55
(-0.42%)
JPY-INR
0.60 0.00
(-0.48%)

EQUITY - MARKET SCREENER

Arihant Academy Ltd
Industry :  Miscellaneous
BSE Code
ISIN Demat
Book Value()
77878
INE0NCC01015
55.3989959
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ARIHANTACA
31.6
290.65
EPS(TTM)
Face Value()
Div & Yield %
15.19
10
0.42
 

USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.